Pediatrix Medical Group (NYSE:MD) Earns Outperform Rating from Analysts at Macquarie

Equities researchers at Macquarie began coverage on shares of Pediatrix Medical Group (NYSE:MD) in a note issued to investors on Monday, Marketbeat reports. The firm set an “outperform” rating and a $18.00 price target on the stock. Macquarie’s target price suggests a potential upside of 26.58% from the company’s current price.

Several other brokerages also recently weighed in on MD. Mizuho boosted their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, November 4th. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Jefferies Financial Group increased their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Finally, StockNews.com raised Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pediatrix Medical Group presently has an average rating of “Hold” and a consensus target price of $16.42.

Pediatrix Medical Group Stock Down 1.6 %

Shares of NYSE:MD opened at $14.22 on Monday. The firm has a fifty day moving average of $14.02 and a 200 day moving average of $10.83. Pediatrix Medical Group has a 52-week low of $6.62 and a 52-week high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The firm has a market capitalization of $1.22 billion, a PE ratio of -4.65, a price-to-earnings-growth ratio of 2.00 and a beta of 1.57.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. During the same period last year, the business earned $0.29 earnings per share. The business’s quarterly revenue was up .9% on a year-over-year basis. As a group, research analysts anticipate that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insider Transactions at Pediatrix Medical Group

In related news, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now owns 138,683 shares in the company, valued at $2,128,784.05. The trade was a 16.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of hedge funds have recently added to or reduced their stakes in MD. Franklin Resources Inc. purchased a new stake in Pediatrix Medical Group during the 3rd quarter valued at $598,000. Barclays PLC increased its holdings in Pediatrix Medical Group by 302.9% during the third quarter. Barclays PLC now owns 142,087 shares of the company’s stock valued at $1,646,000 after buying an additional 106,817 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Pediatrix Medical Group by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock worth $22,452,000 after acquiring an additional 45,155 shares during the last quarter. M&T Bank Corp increased its stake in shares of Pediatrix Medical Group by 20.1% in the 3rd quarter. M&T Bank Corp now owns 85,264 shares of the company’s stock worth $988,000 after purchasing an additional 14,247 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in Pediatrix Medical Group by 54.0% during the third quarter. Jane Street Group LLC now owns 303,283 shares of the company’s stock valued at $3,515,000 after purchasing an additional 106,332 shares in the last quarter. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.